Growth Capital Optikos’ acquisition by Artemis Capital Partners in May 2026 signals new funding and potential strategic expansion. This creates openings for joint business development, market entry into defense, life sciences, and medical devices, and potential channel partnerships with Artemis portfolio companies.

Defense Testing The April 2026 ColliMeter for Riflescopes launch demonstrates strong metrology capabilities for weapon optics. Target rifle scope manufacturers, defense primes, and sporting optics brands with integrated offerings in optical design, testing hardware, calibration, and test automation to support R&D and scalable production.

Imaging Partnerships The December 2025 partnership with Novanta for a dual‑channel fluorescence microscopy system shows leadership in automated imaging with scalable light engines. Approach life sciences instrument builders and contract manufacturers using Novanta platforms to offer optics modules, system integration, and validation services to speed development.

Medical QA ISO 13485 alignment indicates suitability for medical device customers requiring compliant optics and QA processes. Market to medical device OEMs needing optical components, qualification, traceability, and regulatory‑friendly documentation, offering end‑to‑end design, manufacturing support, and validation services.

Global Outreach Active participation in major photonics events such as SPIE Photonics West and Laser World of Photonics signals strong market visibility and pipeline potential. Use these events to demonstrate ColliMeter and other optics capabilities, build distributor and systems‑integrator partnerships, and pursue international sales opportunities.